These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37719011)

  • 1. Corrigendum: A genome-wide investigation of effects of aberrant DNA methylation on the usage of alternative promoters in hepatocellular carcinoma.
    Dong Y; Liu X; Jiang B; Wei S; Xiang B; Liao R; Wang Q; He X
    Front Oncol; 2023; 13():1253552. PubMed ID: 37719011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Genome-Wide Investigation of Effects of Aberrant DNA Methylation on the Usage of Alternative Promoters in Hepatocellular Carcinoma.
    Dong Y; Liu X; Jiang B; Wei S; Xiang B; Liao R; Wang Q; He X
    Front Oncol; 2021; 11():780266. PubMed ID: 35111672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum: Prediction of Microvascular Invasion and Its M2 Classification in Hepatocellular Carcinoma Based on Nomogram Analyses.
    Chen S; Wang C; Gu Y; Ruan R; Yu J; Wang S
    Front Oncol; 2022; 12():888008. PubMed ID: 35449582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: Upregulated LINC01667 Expression Is Correlated With Poor Prognosis in Hepatocellular Carcinoma.
    Zhang K; Liu H; Yu M; Zhao H; Yang N; Bi X; Sun L; Lin R; Lü G
    Front Oncol; 2021; 11():785394. PubMed ID: 34722323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study.
    Wang J; Zheng T; Liao Y; Geng S; Li J; Zhang Z; Shang D; Liu C; Yu P; Huang Y; Liu C; Liu Y; Liu S; Wang M; Liu D; Miao H; Li S; Zhang B; Huang A; Zhang Y; Qi X; Chen S
    Front Oncol; 2023; 13():1278295. PubMed ID: 37719010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum: Blockade of uttroside B-induced autophagic pro-survival signals augments its chemotherapeutic efficacy against hepatocellular carcinoma.
    Nath LR; Swetha M; Vijayakurup V; Thangarasu AK; Haritha NH; Shabna A; Aiswarya SU; Rayginia TP; Keerthana CK; Kalimuthu K; Sundaram S; Lankalapalli RS; Pillai S; Towner R; Isakov N; Anto RJ
    Front Oncol; 2022; 12():991401. PubMed ID: 36091117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum: Real-World Lenvatinib
    Kuo YH; Lu SN; Chen YY; Kee KM; Yen YH; Hung CH; Hu TH; Chen CH; Wang JH
    Front Oncol; 2021; 11():823960. PubMed ID: 34970502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma.
    Hu X; Bao M; Huang J; Zhou L; Zheng S
    Front Oncol; 2020; 10():617539. PubMed ID: 33330112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum: CDT1 is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.
    Cai C; Zhang Y; Hu X; Hu W; Yang S; Qiu H; Chu T
    Front Oncol; 2021; 11():801970. PubMed ID: 34900749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum: High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma.
    Wang X; Xing Z; Chen H; Yang H; Wang Q; Xing T
    Front Oncol; 2023; 13():1134139. PubMed ID: 37025598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum: SPOCK1 promotes the development of hepatocellular carcinoma.
    Váncza L; Karászi K; Péterfia B; Turiák L; Dezső K; Sebestyén A; Reszegi A; Petővári G; Kiss A; Schaff Z; Baghy K; Kovalszky I
    Front Oncol; 2023; 13():1203745. PubMed ID: 37152016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma.
    Che L; Paliogiannis P; Cigliano A; Pilo MG; Chen X; Calvisi DF
    Front Oncol; 2022; 12():874053. PubMed ID: 35494002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma.
    Lai Y; Feng B; Abudoureyimu M; Zhi Y; Zhou H; Wang T; Chu X; Chen P; Wang R
    Front Oncol; 2020; 10():277. PubMed ID: 32195187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum: YY1 Promotes Endothelial Cell-Dependent Tumor Angiogenesis in Hepatocellular Carcinoma by Transcriptionally Activating VEGFA.
    Yang W; Li Z; Qin R; Wang X; An H; Wang Y; Zhu Y; Liu Y; Cai S; Chen S; Sun T; Meng J; Yang C
    Front Oncol; 2021; 11():828861. PubMed ID: 35096629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Identification of Mitochondrial-Related Prognostic Biomarkers Associated With Primary Bile Acid Biosynthesis and Tumor Microenvironment of Hepatocellular Carcinoma.
    Zhang T; Nie Y; Gu J; Cai K; Chen X; Li H; Wang J
    Front Oncol; 2021; 11():843623. PubMed ID: 35111689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: Accelerating Decreases in the Incidences of Hepatocellular Carcinoma at a Younger Age in Shanghai Are Associated With Hepatitis B Virus Vaccination.
    Yu S; Zhu Q; Zheng Y; Wu C; Ren H; Liu X; Liu Z; Li Y; Pan Q; Zheng YJ
    Front Oncol; 2022; 12():950499. PubMed ID: 36203441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum: Comparison of clinical outcomes between cone beam CT-guided thermal ablation and helical tomotherapy in pulmonary metastases from hepatocellular carcinoma.
    Wang F; Fan S; Shi Q; Zhao D; Sun H; Sothea Y; Wu M; Song H; Chen Y; Cheng J; Zeng Z; Yan Z; He J; Liu L
    Front Oncol; 2022; 12():1038584. PubMed ID: 36276122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum: ASPM is a prognostic biomarker and correlates with immune infiltration in kidney renal clear cell carcinoma and liver hepatocellular carcinoma.
    Deng T; Liu Y; Zhuang J; Tang Y; Huo Q
    Front Oncol; 2022; 12():979968. PubMed ID: 36072794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
    Front Oncol; 2023; 13():1233247. PubMed ID: 37427117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum: Loss of TARBP2 Drives the Progression of Hepatocellular Carcinoma
    Li LM; Chen C; Ran RX; Huang JT; Sun HL; Zeng C; Zhang Z; Zhang W; Liu SM
    Front Oncol; 2021; 11():746958. PubMed ID: 34557419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.